Alison Burklund
Co-Founder
Nanopath
Nanopath Inc. has developed a first-in-class molecular diagnostic platform that enables rapid, point-of-care testing for diseases, significantly reducing the time required for accurate diagnosis. This technology addresses the need for timely and accessible molecular testing, particularly in women's health, by providing high-quality results in minutes.
- Biotechnology
- Digital Health
- Healthcare Technology
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Amogha Tadimety
Co-Founder
Product
Problem
Current molecular diagnostic methods often require complex laboratory equipment and trained personnel, leading to long turnaround times and limited accessibility, especially in point-of-care settings. This delay hinders timely clinical decision-making and can negatively impact patient outcomes, particularly in women's health.
Solution
Nanopath is developing a molecular diagnostic platform designed for rapid, point-of-care testing. The platform aims to deliver accurate molecular diagnostic results in minutes, significantly reducing the time required for diagnosis compared to traditional lab-based methods. This technology enables faster clinical decision-making and improved access to molecular diagnostics, particularly in women's health applications. The company's approach focuses on creating scalable and accessible diagnostic solutions.
Target Audience
The primary target audience includes healthcare providers, clinics, and hospitals seeking rapid and accessible molecular diagnostic solutions, particularly for women's health.
Features
- First-in-class molecular diagnostic platform designed for point-of-care use.
- Rapid testing capabilities, providing results in minutes.
- Scalable technology suitable for various clinical settings.
- Focus on women's health applications.